December Warning Letters Addressed API Testing and Microbial Control
This article was originally published in The Gold Sheet
Executive Summary
Analytical shortfalls at active pharmaceutical ingredient manufacturers around the world figured prominently in the nine drug cGMP warning letters that FDA’s center for drugs posted online in December.
You may also be interested in...
Sales & Earnings In Brief
Herbalife raises full-year guidance
‘Shadow’ Factory Challenges Continue For US FDA
Agency wants more information about API suppliers as it winds up case against KV Tech for hidden use of Dr. Reddy’s plant and seeks to find disappearing manufacturer of contaminated OTC eye drops.
US FDA, USP Raise Questions About Valisure’s Assertions Of Benzoyl Peroxide’s Benzene Risks
The US drug regulatory authority and standard-setting organization are evaluating the drug-screening venture’s findings regarding stability and potential carcinogenic risks associated with the widely used acne treatment, which includes Rx formulations.